Skip to content
Open access

GWAS of Tau‐Neurodegeneration Mismatch Identifies New Risk Loci for Susceptibility to Tau

Sep 2026 · CNS Neuroscience & Therapeutics · Vol 32 · 0 citations · 59 references
Medicine

TL;DR

A genome‐wide association study of tau‐related neurodegeneration identified two novel genetic variants in the loci AKAP9 and STXBP6 leading to higher than expected regional neurodegeneration given the tau level.

Abstract

ABSTRACT Background In Alzheimer's disease (AD), neurodegeneration is primarily attributed to the accumulation of tau neurofibrillary tangles. However, the distribution patterns of both tau pathology and neurodegeneration vary across different brain regions and among individuals. Moreover, multiple factors may influence the relationship between tau burden and neurodegenerative processes. Identifying the genetic architecture associated with deviation in the tau‐neurodegeneration relationship can provide deeper mechanistic insights and guide the development of precision medicine strategies. Methods Here, I perform a genome‐wide association study (GWAS) of cortical tau and thickness quantified by positron emission tomography (PET) and magnetic resonance imaging (MRI) in 794 participants from two cohorts of Alzheimer's disease Neuroimaging Initiative (ADNI) and A4. Results A GWAS was identified between the Tau/Neurodegeneration residual and two novel loci on chromosomes 7 and 14, with two SNPs (rs9323573 and rs9784993) exceeding the genome‐wide significance threshold (p ≤ 5 × 10−8). SNP rs9323573 is located in STXBP6 on chromosome 14, while rs9784993 is in AKAP9 on chromosome 7, both of which were directly genotyped. The minor allele G of both SNPs (rs9323573, MAF = 0.221, p = 2.60 × 10−8; rs9784993, MAF = 0.197, p = 4.92 × 10−8) was associated with lower Tau/Neurodegeneration residuals, indicating higher‐than‐expected neurodegeneration given tau levels. Conclusion GWAS of tau‐related neurodegeneration identified two novel genetic variants in the loci AKAP9 and STXBP6 leading to higher than expected regional neurodegeneration given the tau level. Identifying genetic factors involved in tau‐neurodegeneration mismatch may improve our understanding regarding the potential mechanistic downstream leading to susceptibility or resilience to tau pathology.

Read PDF

Similar papers

Open access Aug 2026

Association between Alzheimer’s disease-related genes and neurodegenerative blood-based biomarkers in Indian adults

Rare and common variants in AD- and neurodegenerative biomarker-associated genes with increased frequency in India compared to other populations may impact blood levels of neurodegenerative biomarkers in South Asians.

Hasan Abu-Amara, Wei Zhao, Zheng Li et al. · 0 citations
Open access Sep 2026

748. Tau Pathology Modulates the Association Between Neurodegeneration and Depressive Symptoms in Alzheimer’s Disease

The findings indicate that the relationship between neurodegeneration and depression is stage-dependent and substantially modulated by tau pathology, and the importance of considering both proteopathic stage and preserved insight when interpreting affective symptoms across the Alzheimer’s disease continuum.

J.-W. Lee, D. Kang · 0 citations
Open access Jul 2026

Parallel neuroinflammatory pathways to cerebrovascular burden and amyloid beta in Alzheimer's disease

Higher plasma YKL‐40 was associated with greater white matter hyperintensity (WMH), whereas higher plasma GFAP was related to increased 18F‐florbetapir (FBP) standardized uptake value ratio (SUVR) and higher plasma p‐tau217 was associated with reduced MTL cortical thickness and hippocampal volume.

Batool Rizvi, Jenna N. Adams, Alison R. Bamford et al. · 1 citation
Open access Sep 2026

Pathway-specific polygenic risk scores reveal underlying mechanisms of cerebral small vessel disease

A validated WMH global-PRS is generated showing robust association with cSVD clinical complications and introduce a multi-cohort WMH ps-PRS framework that reveals candidate biological pathways with candidate biological associations across the lifespan and clinical outcomes.

T. D'Aoust, A. Tsuchida, C. Dufouil et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.